Whole genome sequencing of a sporadic primary immunodeficiency cohort
View / Open Files
Authors
Greene, Daniel
Staples, Emily
Farmery, Henry
Simeoni, ilenia
Rivers, Elizabeth
Maimaris, Jesmeen
Penkett, Christopher
Stephens, Jonathan
Deevi, Sri
Sanchis-Juan, Alba
Gleadall, Nicholas
Thomas, Moira
Sargur, Ravishankar
Gordins, Pavel
BAxendale, Helen
Brown, Matthew
Tuijnenburg, Paul
Worth, Austen
Hanson, Steven
Linger, Rachel
Buckland, Matthew
Rayner-Matthews, Paula
Gilmour, Kimberely
Samarghitean, Crina
Seneviratne, Suranjith
Sansom, David
Lynch, Andy
Ellinghaus, Eva
Ellinghaus, David
Jorgensen, Silje
Karlsen, Tom
Stirrups, Kathleen
Cutler, Anthony
Kumararatne, Dinkantha
Chandra, Anita
Edgar, David
Herwadkar, Archana
Cooper, Nichola
Grigoriadou, Sofia
Huissoon, Aarnoud
Goddard, Sarah
Jolles, Stephen
Schuetz, Catharina
Boschann, Felix
Lyons, Paul
Hurles, Matthew
Savic, Sinisa
Burns, Siobhan
Kuijpers, Taco
Turro, Ernest
Ouwehand, Willem
Thrasher, Adrian
Smith, Ken
Publication Date
2020-07-02Journal Title
Nature
ISSN
0028-0836
Publisher
Springer Nature
Type
Article
This Version
AM
Metadata
Show full item recordCitation
Thaventhiran, J., Lango Allen, H., Burren, O., Rae, W., Greene, D., Staples, E., Zhang, Z., et al. (2020). Whole genome sequencing of a sporadic primary immunodeficiency cohort. Nature https://doi.org/10.1038/s41586-020-2265-1
Abstract
Primary immunodeficiency (PID) is characterised by recurrent and often life-threatening infections, autoimmunity and cancer, and it presents major diagnostic and therapeutic challenges. Although the most severe forms present in early childhood, the majority of patients present in adulthood, typically with no apparent family history and a variable clinical phenotype of widespread immune dysregulation: about 25% of patients have autoimmune disease, allergy is prevalent, and up to 10% develop lymphoid malignancies1–3. Consequently, in sporadic PID genetic diagnosis is difficult and the role of genetics is not well defined. We addressed these challenges by performing whole genome sequencing (WGS) of a large PID cohort of 1,318 participants. Analysis of coding regions of 886 index cases found disease-causing mutations in known monogenic PID genes in 10.3%, while a Bayesian approach (BeviMed4) identified multiple potential new candidate genes, including IVNS1ABP. Exploration of the non-coding genome revealed deletions in regulatory regions which contribute to disease causation. Finally, a genome-wide association study (GWAS) identified PID-associated loci and uncovered evidence for co-localisation of, and interplay between, novel high penetrance monogenic variants and common variants (at the PTPN2 and SOCS1 loci). This begins to explain the contribution of common variants to variable penetrance and phenotypic complexity in PID. Thus, a cohort-based WGS approach to PID diagnosis can increase diagnostic yield while deepening our understanding of the key pathways influencing human immune responsiveness.
Sponsorship
Funding for the NIHR-BioResource was provided by the National Institute for Health Research (NIHR, grant number RG65966). We gratefully acknowledge the participation of all NIHR BioResource volunteers, and thank the NIHR BioResource centre and staff for their contribution. JEDT is supported by the MRC (RG95376 and MR/L006197/1). AJT is supported by the Wellcome Trust (104807/Z/14/Z) and the NIHR Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London. KGCS is supported by the Medical Research Council (program grant MR/L019027) and is a Wellcome Investigator. AJC was supported by the Wellcome [091157/Z/10/Z], [107212/Z/15/Z], [100140/Z/12/Z], [203141/Z/16/Z]; JDRF [9-2011-253], [5-SRA-2015-130-A-N]; NIHR Oxford Biomedical Research Centre and the NIHR Cambridge Biomedical Research Centre. EE has received funding from the European Union Seventh Framework Programme (FP7-PEOPLE-2013-COFUND) under grant agreement no 609020- Scientia Fellows. ER is supported supported by the Wellcome Trust [201250/Z/16/Z]. DE is supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept (SysInflame grant 01ZX1306A; GB-XMAP grant 01ZX1709) and funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany`s Excellence EXC 2167-390884018.
The NIHR Cambridge Biomedical Research Centre (BRC) is a partnership between Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, funded by the National Institute for Health Research (NIHR). This research was co-funded by the support listed above and the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (BRC).
Funder references
Medical Research Council (MR/L006197/1)
Medical Research Council (MC_UU_12015/2)
Cambridge University Hospitals NHS Foundation Trust (CUH) (BRC 2012-2017)
Medical Research Council (MR/L019027/1)
Wellcome Trust (091157/Z/10/Z)
Wellcome Trust (100140/Z/12/Z)
Wellcome Trust (107212/Z/15/Z)
Addenbrooke's Charitable Trust (ACT) (64/17 A)
Medical Research Council (MR/K020919/1)
Cambridge University Hospitals NHS Foundation Trust (CUH) (unknown)
Wellcome Trust (091157/Z/10/B)
British Heart Foundation (None)
MRC (MC_UU_00006/2)
Identifiers
External DOI: https://doi.org/10.1038/s41586-020-2265-1
This record's URL: https://www.repository.cam.ac.uk/handle/1810/303205
Rights
All rights reserved
Licence:
http://www.rioxx.net/licenses/all-rights-reserved
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.